1. Home
  2. GERN vs CDNA Comparison

GERN vs CDNA Comparison

Compare GERN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.46

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$18.77

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
CDNA
Founded
1990
1998
Country
United States
United States
Employees
229
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
GERN
CDNA
Price
$1.46
$18.77
Analyst Decision
Hold
Buy
Analyst Count
4
7
Target Price
$2.17
$27.33
AVG Volume (30 Days)
16.5M
634.8K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
$32.27
$12.18
Revenue Next Year
$60.16
$10.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$1.04
$10.96
52 Week High
$2.01
$21.49

Technical Indicators

Market Signals
Indicator
GERN
CDNA
Relative Strength Index (RSI) 41.84 44.69
Support Level $1.20 $18.30
Resistance Level $1.68 $20.94
Average True Range (ATR) 0.16 1.03
MACD -0.04 -0.10
Stochastic Oscillator 5.08 43.04

Price Performance

Historical Comparison
GERN
CDNA

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: